AstraZeneca's Nexium, J&J's Simponi Lead Charge Of New Products To Receive Reimbursement Prices In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A new round of drugs were cleared for market launch in Japan after the latest round of National Health Insurance price listings, and AstraZeneca PLC's blockbuster Nexium (esomeprazole), waning in the West but picking up speed in Asian markets, leads the new wave of products
You may also be interested in...
Takeda Shaves Off European Subsidiaries And U.S. Jobs On Japanese Approval Day
Daiichi Sankyo's Denosumab and Bayer's Xarelto will soon make their appearance in the Japanese market.
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).